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1. Introduction 
According to the World Health Organization, depression is among the leading cause of 
disability worldwide with approximately 121 million people affected 
(http://www.who.int). It is estimated that 5% of men and 9% of women will experience 
depression in a given year (Kessler et al., 2005). Major Depressive Disorder (MDD) is 
characterized by persistent depressed mood or loss of interest or pleasure from daily 
activities.  Additionally, patients may experience feelings of guilt or worthlessness, as well 
as psychomotor, physiological, and cognitive disturbances (DSM IV). Given that the 
etiology of depression is unclear, current antidepressant treatments are ineffective for most 
patients. Presently, less than 30% of patients achieve response or remission (Trivedi et al., 
2006).  Depression is a clinically and genetically heterogeneous disorder, which complicates 
efforts to identify causative factors of disease and replicate findings. In addition, diagnosis 
and therapeutic assessment are primarily based on subjective measures, making patient 
selection and outcome measures amenable to inconsistencies and irreproducibility.  
Biomarkers that objectively establish diagnosis, prognosis, and antidepressant response can 
facilitate research and clinical management of patients with depression. Many analytes, 
including brain-derived neurotrophic factor (BDNF), serotonin transporter, and 
monoamines, have been linked with depressive symptoms and response to antidepressant 
therapy (Manji et al., 2001; Nestler et al., 2002; Thase, 2007). Although much progress has 
been made in identifying neurobiological correlates of depression, it is unclear whether 
these alterations are causally linked or are due to disease and/or treatment.  With the goal 
of facilitating the search for depression biomarkers, this chapter will discuss several key 
molecular and neurochemical alterations that have been linked with depressive disorder.  
2. Genetic studies 
The role of genetics in the development of MDD is supported by findings from family, twin, 
and adoption studies. Studies that compared the prevalence of depression in monozygotic 
versus dizygotic twins indicate a heritability estimate of 35-50% (Bierut et al., 1999; Kendler 
et al., 1993; Sullivan et al., 2000). There is a two-to-threefold increased risk of developing 
MDD among first degree relatives of depressed individuals (Kelsoe, 2004; Sullivan et al., 
2000), indicating that genetic variants can be used as prognostic and diagnostic markers. 
There are two widely used approaches to determine genetic markers of depression. 
Candidate gene analysis examines the frequency of genetic alleles between cases and 
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controls. Hypotheses are generated a priori based on the likelihood that the gene affects the 
risk of depression. Alternatively, advances in genotyping capabilities and more recently, 
gene sequencing, have enabled scientists to look for unbiased genome-wide associations 
between common single nucleotide polymorphisms (SNPs) and behavior.  Genes that confer 
risk to depression have been primarily identified using candidate gene analysis approaches, 
while recent efforts to uncover genetic markers of antidepressant response include the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial and Genome-Based 
Therapeutic Drugs for Depression (GENDEP) study, which looked at genome-wide 
associations of common variants with antidepressant response. Genetic studies of 
depression (Levinson, 2006; Lohoff, 2010; Shyn & Hamilton, 2010) and antidepressant 
response (Crisafulli et al., 2011; Kato & Serretti, 2010; Porcelli et al., 2010)  are reviewed in 
this chapter with a focus on several genes.  
2.1 Genetic predictors of depression and antidepressant response 
Antidepressant medications primarily work on altering neurotransmitters in the brain, thus 
much attention has been given to genes within the monoaminergic pathway (Kato & 
Serretti, 2010). An insertion/deletion polymorphism on the 5’ promoter region of the 
serotonin transporter gene (5-HTTLPR) produces a long (L) allele or a short (S) lower-
expressing allele. The 5-HTTLPR variant alters expression of the serotonin transporter in 
vitro (Lesch et al., 1996) and has been linked with MDD (Caspi et al., 2010; Goldman et al., 
2010; Uher & McGuffin, 2010), neuroticism (Lesch et al., 1996), affective disorder (Collier et 
al., 1996; Lasky-Su et al., 2005), suicidality (Anguelova et al., 2003; P. Y. Lin & Tsai, 2004), 
and anxiety related personality traits (Schinka et al., 2004; Sen et al., 2004). Patients with the 
low expressing allele exhibited increased amygdala activation in response to sad faces 
(Hariri et al., 2002), reduced gray matter volume in amygdala and perigenual cingulate 
cortex (Pezawas et al., 2005), as well as altered functional coupling in both regions (Pezawas 
et al., 2005), thus supporting the role of the serotonin transporter in the development of the 
amygdala-cingulate feedback circuitry. Carriers of the S allele who experienced stressful life 
events in the past were more vulnerable to depression and suicidality (Caspi et al., 2003; 
Kendler et al., 2005). However, several groups did not find an association between 
depression and 5-HTTLPR alone (Middeldorp et al., 2010; Munafo & Flint, 2009; Risch et al., 
2009) or in interaction with stressful life events (Risch et al., 2009).  Homozygous carriers of 
the L allele showed higher response and remission rates (Serretti et al., 2005) and more 
favorable side effect profiles (Kato & Serretti, 2010; Kraft et al., 2007; Murphy et al., 2004), 
which did not replicate to a recent large clinical trial that did not find a link between 5-
HTTLPR and treatment response (Kraft et al., 2007). Altogether, these findings indicate that 
environment must be taken into account when evaluating the potential use of 5-HTTLPR as 
a genetic marker of depression.   
Other genes in the monoamine pathway have been studied for their link with depressive 
behavior. The serotonin-1A receptor (HTR1A) is located in the serotonergic neurons and on 
their post-synaptic targets. In the pre-synaptic neuron, 5HT1A auto-inhibits raphe firing and 
5-HT synthesis. The -1019C/G variant (rs6295) found in the promoter region of HTR1A 
results in higher expression of serotonin-1A auto-receptor (5-HT1A), which leads to 
reduction in serotonergic neurotransmission (Stahl, 1994). The -1019C/G mutation is 
correlated with anxiety and depression (Gross et al., 2002; Lemonde et al., 2004; Strobel et 
al., 2003). In Asians, the G allele is associated with improved treatment outcomes (Hong et 
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al., 2006; Kato et al., 2009).  However, this finding was not observed in Caucasians 
(Lemonde et al., 2004; Serretti et al., 2004), suggesting a confounding effect of race. The 
relationship between HTR2A and antidepressant response is unclear due to conflicting 
results (reviewed in Kato 2010). A recent meta-analysis did not find any association between 
HTR1A and HTR2A and treatment response; however, a polymorphism within HTR2A was 
correlated with tolerability(Kato & Serretti, 2010).  No association has been established 
between HTR2A and MDD (Anguelova et al., 2003).  
The tryptophan hydroxylases 1 and 2 (TPH1 and TPH2) catalyze the rate-limiting step in 5-
HT biosynthesis. A functional variant in TPH2 (Arg441His) results in 80% reduction of 5-HT 
in the brain (X. Zhang et al., 2004) and was found to be more frequent in patients with MDD 
(X. Zhang et al., 2005). However, other studies failed to replicate this finding (Delorme et al., 
2006). Furthermore, the TPH 218A allele is associated with poor antidepressant response 
(Serretti et al., 2001a; Serretti et al., 2001b), a finding that was supported by a meta-analysis 
study (Kato & Serretti, 2010). Patients with the 218 C/C genotype were more likely to 
respond to antidepressant therapy (Kato & Serretti, 2010). Interestingly, the significant 
pooled odds ratio score (OR) was primarily influenced by the sum of the three studies that 
looked at the association between remission rates and the 218 genotype, suggesting that the 
TPH gene may be important in regulating long-term antidepressant response. Of interest is 
the recent correlation between TPH2 haplotype markers and suicidality (De Luca et al., 2004; 
Lopez et al., 2007), suggesting that TPH2 may mediate a subset of depressive symptoms like 
suicidal thoughts and feelings of guilt and worthlessness.  
Enzymes that mediate clearance of catecholamines including, monoamine oxidase A (MAO-
A) and catechol-O-methyl transferase (COMT) have been linked to antidepressant response. 
Higher transcription efficiency is observed with the variable number tandem repeat (VNTR) 
sequence located 1.2kb upstream of the MAO-A gene (Sabol et al., 1998). Alternatively, the 
Val to Met substitution at codon 158 for membrane-bound COMT protein (codon 108 for 
soluble COMT) has been linked to lower enzymatic activity(Mannisto & Kaakkola, 1999) 
and improved response to citalopram (Arias et al., 2006) and mirtazapine (Szegedi et al., 
2005) but not paroxetine (Arias et al., 2006; Szegedi et al., 2005).  
A locus on Chr. 12 has been linked with MDD (Abkevich et al., 2003; McGuffin et al., 2005) 
and anxiety (Erhardt et al., 2007). Within this putative region lies the purinergic ATP-
binding calcium channel gene (P2X7). A non-synonymous coding SNP within P2X7 
(Gln460Arg) is associated with MDD risk (Lucae et al., 2006). P2X7 protein is required for 
IL-1 (interleukin-1) processing and secretion (Ferrari et al., 2006), highlighting the potential 
role of immune function in depressive behavior. Moreover, the FK506 binding protein 5 
(FKBP5) in complex with Hsp90 regulates glucocorticoid receptor sensitivity. A functional 
variant within FKBP5 that results in increased intracellular concentration of FKBP5 has been 
linked with recurrence of depressive episodes (Binder et al., 2004) and antidepressant 
response (Binder et al., 2004; Lekman et al., 2008b). FKBP5 activates glucocorticoid receptors 
and the hypothalamic-pituitary-adrenal axis, which regulate response to stress (Binder et al., 
2004). Additionally, the corticotropin releasing hormone 1 (CRH1) variant is correlated with 
early onset of depressive symptoms (Papiol et al., 2007). CRH activates the HPA axis, thus 
supporting the role of the HPA axis in mediating depressive behavior.  
Small low-powered studies were combined in a meta-analysis to clarify the associations of 
several genes with depression, which were unclear due to inconsistent or non-replicated 
findings. Lopez-Leon et al. found a protective effect for the APOE 2 allele (combined OR, 
0.51; CI, 0.27-0.97) with no evidence of between-study heterogeneity (Lopez-Leon et al., 
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2008). Alternatively, an increased risk were found for the methylenetetrahydrofolate 
reductase MTHFR C677T polymorphism (pooled OR, 1.36),  the guanine nucleotide binding 
protein 3 GNB3 C825T variant (pooled OR, 1.38; CI, 1.13-1.69), and the dopamine transporter 
SLC6A3 40 bp VNTR (pooled OR, 2.06; CI, 1.25-3.40)  (Lopez-Leon et al., 2008).   
Pharmacogenetic studies of antidepressants in the STAR*D trial have identified genes 
associated with treatment response (Hu et al., 2007; Lekman et al., 2008a; McMahon et al., 
2006; Paddock, 2008), treatment resistance (Perlis et al., 2008), and treatment-emergent 
suicidal ideation (Laje et al., 2009; Laje et al., 2007; Perlis et al., 2007). In addition, 
polymorphisms in genes that encode drug-metabolizing enzymes and transporters have 
been tested for correlation with treatment response (Peters et al., 2008). Genes that were 
significantly associated with response to citalopram include FKBP5 (Lekman et al., 2008a), 
glutamate receptor, ionotropic kainite 1 (GRIK1), N-methyl d-aspartate 2A (GRIN2A), 5-
hydrxytryptamine receptor 2A (HTR2A), potassium channel, subfamily K, member 2 
(KCNK2), phosphodiesterase (PDE), and solute carrier family 6 member 4 (SLC6A4) (E. Lin 
& Chen, 2008). 
A link between genes and depression exists, however, putative genes identified to date do 
not significantly account for the phenotypic variance observed (Mann & Currier, 2006).  
Although these initial results may seem disappointing, they indicate that the genetics of 
depression is far from simple. It is likely that multiple genes with minor effect sizes interact 
with environmental factors to affect mood, making identification of genetic biomarkers 
challenging.  Efforts to investigate gene by environmental effects can further delineate the 
contribution of each gene on disease and treatment outcomes (Lesch, 2004; Wermter et al., 
2010). 
3. Biochemical alterations 
Several mechanisms are altered in depression and these include neurotransmission, 
neuroendocrine signaling, and neuroimmune functions. It is unclear whether these 
biochemical alterations are products or causative factors of depression. This section will 
discuss common biological alterations that have been observed in depression, facilitating 
identification of candidate biochemical markers for depression and antidepressant response. 
3.1 Monoamines 
The monoamine theory of depression developed following the observation that iproniazid, a 
drug that inhibits the metabolism of monoamines by blocking MAO, improved the mood of 
patients who are taking the drug (Delay et al., 1952).   In addition, depletion of monoamines 
by agents like reserpine was found to induce depression (Goodwin & Bunney, 1971). This 
theory led to the development of antidepressant drugs that elevate monoamine levels at the 
synapse by blocking uptake transporters, catabolic enzymes or inhibitory pre-synaptic auto- 
or hetero-receptors. The monoamines provided a biochemical basis for depression, whereby 
depression is thought to result from a ‘chemical imbalance’ of monoamines in the brain 
(Schildkraut, 1965).  However, several observations have cast doubt on the major role of 
monoamines in MDD. In addition to the untimely manner in which elevation of monoamines 
occur with respect to symptom resolution (Baldessarini, 1989), treatments that do not elevate 
monoamine levels like electroconvulsive therapy (ECT) have been effectively shown to treat 
depression (Pagnin et al., 2004). The monoamine theory of depression was then modified to 
indicate that elevation of monoamines is the first step in a cascade of molecular events that 
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ultimately leads to symptom improvement (Pineyro & Blier, 1999). Research focus began to 
shift towards evaluating the long-term adaptive changes that result from increased 
monoamines in the synapse. It was hypothesized that elevation in monoamines leads to 
reduction in the sensitivity and/or number of monoamine receptors. Although desensitization 
and internalization of monoamine receptors have been observed in several animal and post-
mortem studies, results were often inconsistent and conflicting (Elhwuegi, 2004). Effective 
antidepressant agents that do not act by inhibiting monoamine reuptake proteins or 
metabolizing enzymes can still facilitate receptor internalization despite the absence of pre-
synaptic input (Fishman & Finberg, 1987; Kientsch et al., 2001). More recently, it has been 
shown that monoamine elevation may lead to cellular genesis. Various antidepressant agents 
including, specific serotonin reuptake inhibitor (fluoxetine), monoamine oxidase inhibitor 
(tranylcypromine), specific norepinephrine reuptake inhibitor (reboxetine), and 
serotonin/norepinephrine uptake inhibitor (tricyclic antidepressants) have been shown to 
induce cell proliferation and neurogenesis (Santarelli et al., 2003), which suggests that 
monoamine elevation leads to other downstream molecular effects that can alter behavior.   
Despite decades of research aimed to evaluate the relationship between depression and 
monoamine alteration, direct evidence supporting the causative role of monoamines in 
MDD is lacking (Nestler, 1998), thus prompting efforts to study other pathways that may 
underlie depressive behavior.  
3.2 Hypothalamic Pituitary Adrenal (HPA) axis 
Dysregulation in the HPA axis, which is characterized by elevated plasma cortisol and CRH 
is a common finding in depressed patients (Holsboer, 2000; Raison & Miller, 2003). In 
response to stress, the parvocellular neurons in the hypothalamus secrete CRH, stimulating 
the release of adenocorticotropin releasing hormone (ACTH) from the anterior pituitary. 
ACTH, in turn, activates the synthesis and release of glucocorticoids (cortisol from humans 
and corticosterone in rodents) from the adrenal cortex. Glucocorticoids negatively regulate 
the HPA axis by inhibiting the synthesis and release of CRH from the hypothalamus.  
Activation of the HPA axis mediates physiologic adaptation to stress, however, persistent 
stimulation can lead to glucocorticoid receptor (GR) desensitization (de Kloet et al., 2005).  
Patients with depression typically exhibit high levels of cortisol in plasma, saliva, and urine, 
as well as an increase in the size and activity of the pituitary and adrenal glands (Nemeroff 
& Vale, 2005). Impairment of the HPA axis, which is primarily characterized by the inability 
to suppress cortisol levels following pharmacologic stimulation of GR by dexamethasone, 
has been observed in depressed patients (Ising et al., 2005; Kunzel et al., 2003; Sher, 2006). 
HPA alterations normalize with antidepressant therapy (Holsboer, 2000) and this is 
associated with less relapse (Ising et al., 2007). Glucocorticoids not only exhibit immune and 
metabolic functions but it also regulates neurogenesis, neuronal survival, hippocampal size 
and structure, and acquisition of new memories (Herbert et al., 2006). Reduced maternal 
handling increases CRH signaling (Ladd et al., 1996) and sustains HPA hyperactivity, 
inducing depressive-like behavior in the pups (Francis et al., 1999; Meaney, 2001). In 
humans, early stressful life event is associated with dysregulated HPA axis (Heim et al., 
2002) and development of depressive symptoms (Chapman et al., 2004; McCauley et al., 
1997). One of the mechanisms by which antidepressants induce hippocampal neurogenesis 
is by activating GR (Anacker et al., 2011), thus implicating a direct relationship between 
HPA axis and neural brain signaling.   
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3.3 Other neuroendocrine markers 
It was discovered that hypothyroidism elicits depressive behavior and that these symptoms 
can be reversed by thyroxine therapy (Asher, 1949). Similar symptoms are observed in 
depression and hypothyroidism, which include dysphoric mood, fatigue, anhedonia, and 
alteration in weight (Jackson, 1998). Low levels of thyroid hormones (T3 and T4) stimulate 
the release of thyrotropin releasing hormone (TRH) from the hypothalamus to the anterior 
pituitary. The pituitary, in turn, releases thyrotropin-stimulating hormone (TSH), which 
leads to the release of triiodothyronine (T3) and thyroxine (T4) from the thyroid. Thyroid 
hormones primarily regulate metabolism but may also be involved in neurotransmission 
(Dratman & Gordon, 1996). Although not all depressed patients display abnormalities in 
thyroid function, alterations have been observed including, elevation in T4 (Baumgartner et 
al., 1988; Kirkegaard & Faber, 1991), lower TSH levels (Maes et al., 1989), as well as blunted 
response of TSH to TRH (Hein & Jackson, 1990; Maes et al., 1989). Type-II deiodinase (D-II) 
catalyzes deiodination of T4 to T3. Psychotropic medications like lithium (Baumgartner et al., 
1994b), desipramine (Campos-Barros et al., 1994), carbamezapine (Baumgartner et al., 
1994a), and fluoxetine (Baumgartner et al., 1994c) stimulate the activity of D-II, indicating 
that mood regulatory agents indirectly regulate T3 levels. Others, however, did not find any 
effects of antidepressant on thyroid function (Brambilla et al., 1982). Interestingly, one study 
found that morning and nocturnal changes in TSH may predict antidepressant response 
(Duval et al., 1996). 
There is increasing evidence implicating the involvement of stress-responsive neuropeptide 
systems in depression and anxiety. The involvement of various neuropeptides has been 
reviewed (Alldredge, 2010; Holmes et al., 2003) and a number of them will be described 
here. Administration of neuropeptide antagonists/agonists results in altered responses in 
rodent models of anxiety and depression (Rotzinger et al., 2010). Stress stimulates the 
release of vasopressin, which in turn enhances the effects of CRH on ACTH (G. Aguilera et 
al., 2003; Engelmann et al., 2004; J. N. Zhou et al., 2001). Depressed patients display altered 
levels of vasopressin in the suprachiasmatic nucleus (SCN) (J. N. Zhou et al., 2001), 
paraventricular nucleus (Purba et al., 1996), and supraoptic nucleus (Meynen et al., 2006). A 
polymorphism in the vasopressin receptor (V1B) may be protective against MDD (Overstreet 
& Griebel, 2005; Salome et al., 2006). Antagonism of the V1B receptor reduced depressive-like 
behavior (Griebel et al., 2002), which was comparable to treatment with antidepressant 
agents (Salome et al., 2006). This effect was mainly due to inhibition of the V1B receptors in 
the lateral septum and amygdala (Stremmelin 2005). Similar to vasopressin, neuropeptide Y 
(NPY) is released under stress. NPY is abundantly expressed in the brain and is co-localized 
with noradrenaline, somatostatin, and GABA (┛-aminobutyric acid) (Kask et al., 2002). 
Reduction in NPY is associated with increased sensitivity to depression and stress, 
indicating that NPY agonists may exhibit antidepressive effects (Redrobe et al., 2002). A 
variant in the promoter region of Npy alters the expression of NPY in vivo and is linked with 
anxiety behavior and neural responses to stress (Z. Zhou et al., 2008). Substance P (SP), a 
known modulator of pain signaling, has been shown to interact with serotonergic signaling 
(Schwarz et al., 1999). Substance P binds to neurokinin-1 (NK1) receptors found in the brain 
and in the periphery. Genetic ablation or pharmacologic antagonism of NK1 receptors 
promotes monoaminergic activity (Froger et al., 2001; Maubach et al., 2002; Santarelli et al., 
2001) and reduces anxiety-like behavior (Santarelli et al., 2001).  Depressed patients have 
higher SP levels in the serum (Bondy et al., 2003). Interestingly, NK1 antagonists activate the 
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serotonergic system similarly to serotonin reuptake inhibitor (escitalopram)(Guiard et al., 
2004), indicating  that NK1 antagonists may have antidepressive effects. Galanin is a 29-30 
amino acid peptide that regulates various physiological responses like metabolism and food 
intake. Galanin binds to several galanin receptors (GALR), which in turn interacts with 
different G proteins, activating various signal transduction pathways (K. E. Smith et al., 
1998; Wang et al., 1998).  Galanin administration in rodents produces a variety of effects 
including, nerve regeneration, nociception, and alteration in sexual and feeding behavior 
(Wrenn & Crawley, 2001; Yoshitake et al., 2003). Galanin mediates 5-HT and norepinephrine 
levels (Ogren et al., 2006) and antagonism of GALR can enhance or reduce depressive-like 
behavior depending on which GALR subtype is being inhibited (Barr et al., 2006; X. Lu et al., 
2005).  
Many years of research implicate the role of the neuroendocrine system in depression. Most 
neuroendocrine regulatory mechanisms occur through the bidirectional communication 
between the hypothalamus and pituitary. These findings indicate that the neural circuitry, 
neuronal signaling, and structural plasticity within this region are likely to be critical in 
behavioral responses.  
4. Metabolic alterations 
Metabolic syndrome is comprised of several features including, central obesity and insulin 
resistance, which, in concert, increases risk for developing cardiovascular disease and 
diabetes. Compared to healthy controls, depressed individuals are more likely to develop 
obesity, diabetes, and hypertension (Lindley et al., 2009), indicating potential overlap 
between depressive symptoms and metabolic syndrome. Independent of the criteria used to 
define metabolic syndrome (Raikkonen et al., 2007), a strong bidirectional association 
between depression and metabolic syndrome exists in women (Gil et al., 2006; Kinder et al., 
2004; Raikkonen et al., 2007). The correlation between depressive symptoms and metabolic 
syndrome is slightly higher in monozygotic twins than dizygotic twins, suggesting that 
genetics play a critical role in both disorders (McCaffery et al., 2003). Resistance to insulin, 
which is a risk factor for developing metabolic syndrome, is a common occurrence in 
depressed patients (Koslow et al., 1982; Okamura et al., 2000; Winokur et al., 1988), which 
suggests that insulin links depression with metabolic syndrome. Insulin exerts dose-
dependent effects on food intake and energy regulation. Ablation of insulin receptors on 
neuronal cells leads to an increased in body fat disposition, suggesting that insulin 
negatively regulates adiposity (Bruning et al., 2000). Additionally, insulin regulates 
monoamine uptake and metabolism, phosphoinositol turnover, as well as norepinephrine 
and dopamine transporter mRNA levels (Craft & Watson, 2004). It has been shown that 
insulin can recruit GABA receptors (Wan et al., 1997) and promote internalization of ┙-
amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors, which suggests 
that insulin plays a critical role in neuronal signaling and synaptic plasticity (Huang et al., 
1998). Interestingly, brain volume abnormalities and neurocognitive deficits commonly 
found in MDD patients have been observed in individuals with diabetes mellitus (DM), 
suggesting overlapping pathophysiology between MDD and DM (McIntyre et al., 2010). 
Insensitivity to insulin likely develops due to HPA axis hyperactivity (Rizza et al., 1982), 
impaired immune system (Fernandez-Real et al., 2001; Maes, 1995; Moller, 2000), and altered 
central serotonergic signaling (Goodnick et al., 1995; Horacek et al., 1999), all of which are 
common findings in depressed patients (Belmaker, 2008; Krishnan & Nestler, 2008). 
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Association between depression and obesity has been identified in several cross sectional 
studies (de Wit et al., 2010; Faith et al., 2002; Scott et al., 2008). A recent meta-analysis looked 
at the association between obesity and depression in a community-based setting and found 
that obese patients have an 18% increased risk of developing depressive symptoms (overall 
OR, 1.18) (de Wit et al., 2010). Subsequent sub-group analyses showed that the association 
with obesity holds true for depressed women but not for men, which suggests that 
comorbidity is likely to be affected by sex (de Wit et al., 2010).  Similarly, a meta-analysis of 
longitudinal studies showed that baseline obesity increased the risk of depression (pooled 
OR, 1.57) and that depression increased the odds for developing obesity (pooled OR, 1.40). 
Prospective analysis of the cause-effect relationship between obesity and depression indicate 
reciprocal findings, whereby obesity was found to be a predictor of depression in eight out 
of the ten studies reviewed, while 53% of the studies found that depression predicts obesity 
(Faith et al., 2011). Interestingly, the positive association between depression and obesity is 
only detected in studies conducted in the United States but not in other European countries, 
indicating a strong contributory effect of environment (Atlantis & Baker, 2008). It is 
increasingly recognized that similar neural circuitry that regulate memory, reward, mood, 
and emotion also controls appetite, body weight, and energy homeostasis (Dallman, 2009; 
Zheng et al., 2009). Food induces olfactory and visual sensory inputs, which stimulate the 
orbitofrontal cortex, where acquisition, storage, and processing of memory and experiences 
associated with food is thought to occur (Verhagen, 2007). Stimulation of the mu-opioid 
receptor in the nucleus accumbens and ventral pallidum results in further intake of 
pleasurable foods (Will et al., 2003; M. Zhang & Kelley, 2000). The ventral tegmental area 
and the nucleus accumbens are part of the mesolimbic dopaminergic system, which 
regulates behavioral response (motivation) towards favorable stimuli (Berridge, 1996, 2007; 
Pecina et al., 2006), indicating that food intake and motivation are, at least partly, co-
regulated by similar circuitry. The hypothalamus regulates homeostatic responses to altered 
nutrient levels and adiposity levels (Berthoud, 2002; Xue & Kahn, 2006) through various 
endocrine hormones including, leptin (Farooqi et al., 2002; Friedman, 1999; O'Rahilly, 2002) 
and NPY (Luquet et al., 2005). Although leptin is primarily known for its role in appetite 
suppression and energy expenditure, leptin also mediates reproduction and cognition 
(Chehab, 2000; Farr et al., 2006). Independent of body mass, depressed patients show lower 
plasma levels of leptin (Jow et al., 2006; Kraus et al., 2001) although other studies did not 
find similar results (Antonijevic et al., 1998; Deuschle et al., 1996; Rubin et al., 2002). Rodents 
exposed to chronic unpredictable stress showed reduction in sucrose preference and higher 
depressive-like behavior, which was reversed by leptin administration, indicating that leptin 
exhibits antidepressive effects likely through innervations of the limbic brain circuitry (X. Y. 
Lu et al., 2006). In response to stressful events, leptin suppresses CRH, ACTH, and 
corticosterone secretion, suggesting a direct impact of leptin on the HPA axis (Ahima et al., 
1996; Heiman et al., 1997; Huang et al., 1998). In addition, leptin-deficient ob/ob mice display 
altered Slc6a4 expression (Collin et al., 2000), decreased neuronal and glial cells, and 
reduced brain weight and cortical volume (Ahima 1999, Stepan 1999), further supporting the 
role of leptin in MDD.  
A common thread between MDD, DM, and heart disease exists. The co-occurrence and 
pathophysiologic overlap between metabolic syndrome, obesity, and depression may 
explain the significant association between depression, diabetes, and cardiovascular disease 
(Frasure-Smith et al., 1993; Goldney et al., 2004; Paile-Hyvarinen et al., 2007).     
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5. Neuroimmune 
An interaction between behavior and the immune system was first recognized in 200 AD, 
when Galen observed that melancholic women were more susceptible to cancer (Leonard, 
1988). Depressed patients exhibit reduced neutrophil phagocytosis, natural killer cell 
activity, and mitogen stimulated lymphocyte proliferation (Irwin et al., 1990). Furthermore, 
patients with MDD show increased cytokine secretion from activated macrophages and 
elevated acute phase proteins in the liver (Sluzewska et al., 1996), indicating dysregulation 
in immune response. Antidepressants inhibit the ability of lipopolysaccharide (LPS) to 
induce the synthesis and the release of pro-inflammatory cytokines, likely through elevation 
of cyclic adenosine monophosphate (cAMP) levels (Xia et al., 1996). It has been 
hypothesized that abnormal secretion of macrophage monokines leads to depressive 
behavior (R. S. Smith, 1991). Macrophages secrete neuroendocrine and immune modulators, 
including, interleukins (IL), tumor necrosis factors (TNF), ACTH, and endorphins (Nathan, 
1987), thus indicating a regulatory role for macrophages in mediating the neuro-endocrine-
immune interface. 
A bidirectional relationship between the brain, neuroendocrine, and immune systems exists, 
particularly in response to stress. Overactivity of the HPA axis, which is a common finding 
in depressed individuals (Holsboer, 2000; Raison & Miller, 2003), results in 
hypercortisolemia and suppression of the immune system. Conversely, persistent stress can 
result in fewer B cells, T cells, and lymphocytes (Olff, 1999), which can confer susceptibility 
to infections and cancer (Garssen & Goodkin, 1999; Kiecolt-Glaser et al., 1995; Reiche et al., 
2005). Stressful events like separation or divorce are correlated with increased cancer risk, 
low proportions of NK and T cells, impairment of DNA repair, and abnormal immune 
response (Kiecolt-Glaser et al., 1987). The presence of reactive oxygen species has been 
detected in depressed patients (Irie et al., 2005). Levels of 8-hydroxydeoxyguanosine (8-OH-
dG), a biomarker of cancer-related oxidative DNA damage, is positively correlated with 
depressive symptoms (Irie et al., 2005), which suggests that depression may be associated 
with cancer.  
In 1987, Wagner-Jauregg demonstrated that activation of the immune system can affect 
various mental states (Raju, 1998). Cytokines regulate growth, differentiation, and function 
of many cells (Turnbull & Rivier, 1999). They can be broadly classified as pro-inflammatory 
or anti-inflammatory cytokines. Pro-inflammatory cytokines like interleukin-1 (IL-1), 
interleukin-6 (IL-6), and TNF-┙ stimulate immune cell production, activation, and 
proliferation. On the other hand, anti-inflammatory cytokines including, interleukin-4 (IL-4), 
interleukin-10 (IL-10), and interleukin-13 (IL-13) dampen the immune response. The role of 
cytokines in depression was identified following observation that interferon treatment 
induces ‘sickness behavior,’ which mimics depressive symptoms such as dysphoric mood, 
fatigue, anorexia, weight loss, and altered sleep patterns (Papanicolaou et al., 1998; Yirmiya, 
2000). Depression is characterized by elevation of pro-inflammatory markers IL-6, c-reactive 
protein (CRP) (Maes, 1995), IL-1, and IL-2 (Dunn et al., 2005; Song et al., 1994). Treatment 
with LPS stimulated depressive-like behavior and cytokine secretion, which were reversed 
by antidepressants or cytokine antagonists (Yirmiya, 2000). Administration of IL-6 and IL-1 
results in elevation of vasopressin, cortisol, CRH, and ACTH (Brebner et al., 2000; Harbuz et 
al., 1992; Xu et al., 1999), which suggests a pivotal role of cytokines in HPA axis activation 
(Dentino et al., 1999). In rodents, treatment with IL-1 resulted in increased DA, NE, and 5-
HT activity in the brain (Dunn & Swiergiel, 1999; Merali et al., 1997; Song et al., 1999). 
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Cytokines acutely stimulate 5-HT neurotransmission and reduce its production by 
stimulating indoleamine 2,3-dioxygenase (IDO), an enzyme that converts the precursor of 5-
HT (tryptophan) into kynurenine (Wichers & Maes, 2002). Pro-inflammatory cytokines have 
been shown to up-regulate serotonin transporter (Morikawa et al., 1998; Mossner & Lesch, 
1998; Wichers & Maes, 2002), while anti-inflammatory cytokines like IL-4 reduces 5-HT 
uptake (Mossner et al., 2001). Together, these findings suggest that cytokines affect 
depressive behavior likely through regulation of monoamines and the HPA axis.  
The symptom heterogeneity observed in depressed patients suggests that biological 
abnormalities are likely to be patient-dependent and disease-specific. Collectively, these 
results indicate that biochemical mechanisms likely interact to mediate a complex behavior 
like mood and anhedonia. It is therefore unlikely that a single biological marker will 
characterize a heterogeneous disorder like depression. Significant benefits can be rendered 
in evaluating the behavioral effects of a panel of biological markers or biochemical 
signatures, particularly since reciprocal communication between nervous, endocrine, and 
immune systems have been noted (Cserr & Knopf, 1992; Felten, 1991; Reichlin, 1993). For 
most cases, when associations between biochemical alterations and depression are detected, 
the causal relationship is often poorly understood. 
6. Brain and molecular correlates  
Direct and indirect evidence from neurostructural, neurofunctional, and molecular studies 
indicate impairments in neural circuitry, structural plasticity, and cellular resilience. These 
abnormalities reflect the molecular neurobiological underpinnings of depression as 
discussed below. 
6.1 Neurostructural and neurofunctional studies  
The cortical-limbic circuitry is implicated to mediate emotional processing in depressed 
patients (Davidson et al., 2002; Dougherty & Rauch, 1997; Mayberg, 1997). Results from 
positron emission tomography (PET) studies indicate that unmedicated patients with MDD 
exhibit increased activity and cerebral blood flow (CBF) to the amygdala, orbital cortex, and 
medial thalamus, as well as decreased CBF to the pre-frontal cortex (PFC) and anterior 
cingulate cortex (ACC) (Drevets, 2000a; Drevets et al., 1999).  Meta-analyses of structural 
neuroimaging studies indicate that MDD is characterized by reduction of gray matter 
volumes in the ACC (Koolschijn et al., 2009), subgenual cingulate cortex (Hajek et al., 2008), 
and hippocampus (McKinnon et al., 2009). Post-mortem neuropathological studies have 
shown that patients with MDD show reduced cortex volume, decreased number of glial 
cells, and/or reduced neuron sizes (Ongur et al., 1998; Rajkowska, 2000; Rajkowska et al., 
1999). Given the functional roles of specific brain regions in emotional processing, 
neuropathological abnormalities observed in depression suggest that areas that mediate 
autonomic and neuroendocrine responses (amygdala) is associated with increased activity 
and cerebral blood flow, while reduction in activity is observed in brain regions that control 
emotional processing (cortex) (Manji et al., 2001). Antidepressant treatment reduces CBF 
and metabolism in the amygadala (Drevets, 2000b; Drevets et al., 1999), attenuating 
hyperresponsiveness to stress (Rosenkranz et al., 2010). Similarly, larger hippocampal 
volume (Frodl et al., 2008; Kronmuller et al., 2008; MacQueen et al., 2008) and gray matter 
density in the ACC (Costafreda et al., 2009) were positively correlated with antidepressant 
response.   
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Inferences regarding the structural integrity of neural tracts can be made through diffusion 
tensor imaging (DTI), which measures the diffusion properties of water through brain 
tissues, in vivo. Patients that did not respond to 12 weeks of escitalopram (Alexopoulos et al., 
2008) or citalopram (Alexopoulos et al., 2002) treatment showed microstructural 
abnormalities in white matter pathways connecting the cortex with the limbic and 
paralimbic areas, which indicates that poor therapeutic outcome is related to impaired 
cortical-limbic connectivity (Mayberg, 2003). Patients with prior exposure to parental verbal 
abuse (Choi et al., 2009) or have genetic polymorphisms (5-HTTLPR) (Alexopoulos et al., 
2009) exhibit microstructural white matter abnormalities, suggesting that neural brain 
structure is subject to genetic and environmental control. Of note, impairment in brain 
morphology, neural circuitry, and brain function have been linked with monoaminergic and 
non-monoaminergic genetic variants (Scharinger et al., 2010).  In addition to evaluating the 
structural integrity of neural brain circuits, functional activity within the limbic-cortical 
circuitry has been investigated. Brain activity can be evaluated by measuring blood oxygen 
level-dependent (BOLD) signals while patients are resting (intrinsic activity) or when 
performing a task (task-related activity). BOLD signaling is associated with changes in blood 
flow and tissue oxygen concentration, which are markers of brain activity. Depressed 
individuals have reduced activity in the limbic and cortical regions (Anand et al., 2005), 
which normalizes as symptoms resolve (Anand et al., 2005). Patients with MDD show 
hyperactivity in the amygdala (Surguladze et al., 2005) and reduced co-activation of the 
dorsal ACC (Matthews et al., 2008) when viewing negative facial expressions. These changes 
in brain activity are ameliorated with chronic antidepressant treatment (Chen et al., 2008; Fu 
et al., 2004; Sheline et al., 2001).  
Similar to the electrocardiogram (ECG), unfiltered electrical activity generated by the brain 
can be measured by an electroencephalogram (EEG). EEG signals can be converted to show 
a topographical representation of the distribution of the EEG waveforms across the cortex 
known as the quantitative electroencephalograph (QEEG) brain map. The QEEG image is 
used to assess brain activity and metabolism in real-time, providing a global assessment of 
brain activity. Brain electrical activity can be measured using cordance, low-resolution brain 
electromagnetic tomography (LORETA), and antidepressant treatment (ATR) index. 
Cordance, which uses QEEG measurements conducted from a full scalp electrode array, 
assesses perfusion of cerebral cortex and brain activity on cortical convexities like PFC 
(Cook et al., 1998; Leuchter et al., 1999). Several groups have demonstrated the usefulness of 
cordance in characterizing antidepressant response (Bares et al., 2008; Cook et al., 2002). 
Responders and non-responders differ in QEEG measurements at rest and during task-
oriented activities (Bruder et al., 2008).  LORETA, which assesses activity of deeper cortical 
regions like ACC and orbitofrontal cortex (Pizzagalli et al., 2001), identifies cortical 
alterations in relation to depression and antidepressant response (Anderer et al., 2002; Saletu 
et al., 2010). Both cordance and LORETA require whole-head electrode montages for data 
collection, which entails up to 75 minutes of QEEG recording, limiting its clinical utility. On 
the other hand, the ATR only uses a five-electrode montage placed on the frontal brain 
regions, which limits QEEG recording to 10 minutes (Leuchter et al., 2009a; Leuchter et al., 
2009b). The largest study that evaluated the use of ATR in predicting antidepressant 
response is the Biomarkers for Rapid Identification of Treatment Effectiveness trial in Major 
Depression (BRITE-MD) trial. In this study, positive ATR predicted response and remission 
to escitalopram. Patients with negative ATR values were either switched to bupropion or 
continued to be treated with escitalopram. In comparison to patients who stayed on 
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escitalopram, patients who switched to bupropion were 1.9 times more likely to respond to 
treatment (Leuchter et al., 2009a; Leuchter et al., 2009b). These results support the use of 
ATR as a biomarker for monitoring treatment response and clinical progression. 
6.2 Cellular and molecular markers 
Lower hippocampal volume (Videbech & Ravnkilde, 2004), which is commonly found in 
post-mortem brain tissues of depressed individuals (MacQueen et al., 2003), results in 
reduced hippocampal plasticity. Reduction in neurogenesis, brain volume, and thickness is 
likely due to decreased neurotrophins and/or changes in neuroplasticity (Geuze et al., 
2005). Neurotrophins, including brain-derived neurotrophic factor (BDNF), have been 
repeatedly implicated in the pathogenesis and treatment of MDD (Duman & Monteggia, 
2006). Administration of BDNF induces cell proliferation and neurogenesis (Pencea et al., 
2001; Zigova et al., 1998), and leads to lower  depressive-like behavior (Shirayama et al., 
2002; Siuciak et al., 1997). Neurogenesis, resulting from either antidepressant treatment or 
cell implantation, attenuates depressive behavior (Tfilin et al., 2009). Depressed patients 
show reduced BDNF levels (Sen et al., 2008), which can result in lower number of dendrites 
in the synapse (Manji et al., 2003; Nestler et al., 2002). Antidepressants stimulate BDNF 
synthesis (Duman, 2004) and normalizes  reduced BDNF levels in depressed patients 
(Brunoni et al., 2008; Sen et al., 2008). A functional variant at codon 66, resulting in a 
valanine to methionine change (Val66Met), is reported to correspond with drug response. 
Carriers of the Met allele were reported to have better treatment outcomes (Gratacos et al., 
2008; Kato & Serretti, 2010), however, others did not find any correlation between the 
Val66Met variant and treatment response (Kato & Serretti, 2010; Tsai et al., 2003; Wilkie et 
al., 2007). Furthermore, genetic susceptibility to depression was not associated with the 
BDNF Val166Met variant (Gratacos et al., 2007; Lopez-Leon et al., 2008). The Met allele is 
associated with impaired intra-cellular packaging and activity dependent secretion of 
BDNF, which disrupts hippocampal function (Egan et al., 2003). Impaired suppression of 
the HPA axis following dexamethasone treatment was also observed in the BDNF Met 
carriers (Schule et al., 2006). Of note, mouse lines that did not express Bdnf during fetal 
development or post-natal development were hyperactive, hyperaggressive, and showed 
higher depressive-like behavior compared to transgenic mice that were conditioned to 
express Bdnf during post-natal development (Chan et al., 2006), suggesting that the 
behavioral effects of BDNF are region and time-dependent. Interestingly, an interaction 
between the BDNF G196A variant, the serotonin transporter gene, and stressful life events 
has been observed (M. Aguilera et al., 2009; Pezawas et al., 2008). 
BDNF is activated by cyclic-AMP response element-binding protein (CREB). The cAMP-
CREB cascade has been extensively studied for its involvement in cell survival and neural 
plasticity (D'Sa & Duman, 2002; Duman et al., 1997). The cAMP-CREB pathway is 
upregulated following chronic antidepressant treatment (Duman et al., 1999). Activation of 
the CREB pathway is thought to result in neurogenesis. Activated or phosphorylated CREB 
is found in actively dividing neural progenitor cells in the hippocampal subgranular zone 
(SGZ) (Nakagawa et al., 2002a). Mice lacking Creb show markedly reduced cell proliferation 
(Nakagawa et al., 2002b) and administration of a phosphodiesterase inhibitor, which 
activates the cAMP cascade, increases neurogenesis and improve depressive behavior 
(Takahashi et al., 1999).  Although CREB plays a critical role in neurogenesis, CREB is not 
necessary to elicit antidepressant effects. After antidepressant treatment, no difference in 
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depressive-like responses was observed between Creb deficient mice and wild-type controls, 
indicating that the behavioral effects of antidepressant drugs may occur through other 
CREB-independent mechanisms.   
Given that depressed patients exhibit reduced neuronal and glial cells, molecular 
mechanisms that stimulate neurogenesis (activation of CREB and BDNF synthesis) are likely 
to be critical in MDD. Presently, the clinical significance of cellular genesis in depression is 
largely unknown. It is likely that cellular proliferative and survival processes interact to 
facilitate remodeling of synaptic connections that can lead to altered mood. It is noteworthy 
to consider, however, that in the absence of stress, the neural circuitry underlying 
depression may be different (Krishnan & Nestler, 2008). There is a possibility that  reversal 
of stress-induced neural plasticity changes is not required for antidepressive effects (Nestler 
et al., 2002).    
7. Depression signatures 
7.1 Gene expression signatures 
Gene expression profiling studies provide an unbiased look at the relationship between 
gene expression and depressive disorder, which is useful in identifying novel targets for 
antidepressant therapy (for a detailed review see Sequeira & Turecki, 2006). Bernard and 
colleagues collected gene expression data from the locus coeruleus of healthy, depressed, 
and bipolar patients. In this study, they found significant alterations in patients with MDD 
but not bipolar subjects. Gene expression alterations were detected in the glutamate 
signaling genes (SLC1A2, SLC1A3 and GLUL), growth factor genes (FGFR3 and TrkB), and 
several astroglial genes (Bernard et al., 2010). Similarly, dysregulation of fibroblast growth 
factor genes (FGF1, FGF2, FGFR2, and, FGF3) were detected in cortical regions of depressed 
patients, irrespective of previous antidepressant treatment (Evans et al., 2004). Consistent 
with previous findings, expression of genes involved in signal transmission of glutamate 
and GABA were found to be dysregulated in depressed patients (Choudary et al., 2005) and 
in suicide victims with and without depression (Sequeira et al., 2009). Alteration in genes 
regulating oligodendrocyte function (Sequeira & Turecki, 2006) and cell-cell communication 
(Sequeira et al., 2009) were altered in MDD, suggesting impairment in brain circuitry. 
Notably, reduced oligodendrocyte expression and neuronal changes in amygdala were 
detected in both depressed individuals and in rodents exposed to unpredictable chronic 
mild stress (Sibille et al., 2009), indicating a connection between stress response and neural 
circuitry.  
For biomarkers to be clinically useful, putative analytes must be detected in easily accessible 
samples like plasma or serum.  Using LPS-stimulated blood samples, Spijker et al. compared 
gene expression profiles between healthy and unmedicated patients with MDD. A 
significant difference in gene expression pattern was observed in a subset of genes, all of 
which have not been previously associated with depression (Spijker et al., 2010). 
Transcriptome changes in the leukocyte mRNA is correlated with response to 
antidepressant agents or lithium therapy (Iga et al., 2008). The authors found that 
normalization in gene expression pattern correlates with antidepressant response (Iga et al., 
2008).  In addition to analyzing global changes in the brain or plasma transcriptome, genetic 
regulatory elements of depression or antidepressant response can be identified using 
quantitative trait loci (QTL) mapping analysis. In this approach, DNA variants that regulate 
gene expression locally or distally (cis or trans-regulatory elements) are analyzed for 
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correlation with depressive behavior, thereby facilitating analysis for regulatory genes 
underlying depressive behavior. This approach has been used to detect regulatory genetic 
elements for several behaviors (Bryant et al., 2009; Radcliffe et al., 2006).  
7.2 Protein signatures 
Other efforts to identify depression signatures include protein expression profiling. Plasma 
samples from control, depressed, and schizophrenic patients were analyzed for 79 plasma 
protein biomarkers including, cytokines, neurotrophins, and chemokines (Domenici et al., 
2010). Interestingly, insulin and matrix metallopeptidase 9 (MMP-9) displayed the biggest 
difference between control and depressed patients (Domenici et al., 2010). Efforts to expand 
the panel of protein markers to include peripheral and neuropsychological markers are 
currently underway (Tadic et al., 2011). The global analysis of protein expression is still in its 
infancy although several groups have performed proteomic analysis in the  cerebrospinal 
fluid (CSF) (Raedler & Wiedemann, 2006) and in discrete brain regions collected post-
mortem (Beasley et al., 2006). In order to characterize the cause-effect relationship between 
biological alterations, treatment, and behavior, protein profiling studies in human samples 
should be complemented with proteomic studies in animals, which are more amenable for 
determination of disease and treatment effects.    
8. Other mechanisms 
8.1 Epigenetics 
Discordance of depression between monozygotic twins suggests other non-genetic factors 
are involved (Mill & Petronis, 2007). Alteration in gene expression can occur without 
changes in the DNA sequence through epigenetic mechanisms like histone modification and 
methylation of DNA CpG islands. Deacytelation of histones results in DNA coiling, which 
prevents binding of transcription factors to the DNA, suppressing gene transcription. 
Alternatively, methylation alters DNA chemistry, which blocks gene transcription. 
Epigenetic mechanisms can explain how genetically weak signals of risk combined with 
environmental factors predispose patients to depression (Caspi & Moffitt, 2006).  
Adverse childhood experiences confer risk to depressive behavior (Heim & Nemeroff, 2001) 
likely through epigenetic alteration.  Offspring who received minimal maternal care had 
higher DNA methylation at the glucocorticoid receptor (GR) promoter region and were 
more responsive to stress compared to control animals (Liu et al., 1997; Weaver et al., 2004). 
Methylation in the GR promoter region leads to reduced binding of the nerve growth factor 
induced protein-A (NGF-1A), affecting GR regulation (Weaver et al., 2004; Weaver et al., 
2007). Notably, low levels of maternal care led to epigenetic repression of the estrogen-alpha 
receptor that resulted in transmission of maternal behavior to offspring (Champagne et al., 
2006; Champagne et al., 2003), thus indicating transgenerational phenotypic transfer 
through epigenetic alterations.   
Mice that are deficient in Hdac5 display enhanced vulnerability to stress, suggesting that 
stress reduces histone deacytelase activity leading to down-regulation of gene expression 
(Renthal et al., 2007). The adverse effect of stress on Hdac5 activity is reversed by chronic 
antidepressant treatment (Renthal et al., 2007).  Antidepressant treatment increases histone 
acetylation at the Bdnf promoter region, activating Bdnf expression (Tsankova et al., 2006). 
BDNF mediates formation and differentiation of new neurons, facilitating long-term 
potentiation and memory development.  
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RNA-mediated modifications through non-coding RNAs (ncRNA) and microRNAs 
(miRNA) can activate or silence gene transcription. The role of miRNA in regulating 
serotonergic transmission has been reviewed (Millan, 2011). MicroRNAs are short RNAs 
(22-24 nucleotides) that bind to complementary sequences on target mRNAs, typically 
leading to gene silencing (Bartel, 2009; Carthew & Sontheimer, 2009; Winter et al., 2009). A 
recent study by Baudry et al. shows that miR-16 negatively regulates the expression of 
serotonin transporter (SERT). Fluoxetine treatment stimulates the release of S100 calcium 
binding protein B (S100┚) in the raphe, leading to elevation of miR-16 and reduction in SERT 
(Baudry et al., 2010). MiR-16 also represses the expression of anti-apoptotic protein (B-cell 
lymphoma 2) Bcl-2 (Cimmino et al., 2005), indicating a critical role of miR-16 in 
neurotransmission as well as cell proliferation. In addition, genetic studies using seahare 
(Aplysia) identified miR-124 as a translational repressor of CREB, which suggests that 
microRNAs indirectly regulate secondary messenger pathways by modulating CREB 
expression (Rajasethupathy et al., 2009). Overexpression of ncRNA was found in 
Alzheimer’s patients (Faghihi et al., 2010), however, an association between ncRNA and 
depression is yet to be established.   
Consistent with the notion that genes are interconnected within a network, it is conceivable 
that an epigenetic regulatory network exists.  Efforts to identify epigenomic signatures are 
underway (Akbarian & Huang, 2009) and this data should be integrated with other data sets 
like the brain transcriptome and behavior to identify causative pathways in depression. Of 
great interest is the assessment of epigenetic transgenerational transmission of a trait and 
genomic imprinting (epigenetic alteration on gene expression is based on whether the gene 
is inherited from the father or the mother). These epigenetic phenomena facilitate our 
understanding of how environment and genetics interact to mediate behavior, ultimately 
providing a comprehensive picture of the molecular mechanisms underlying depression.   
8.2 Sleep and circadian rhythm 
It was previously thought that insomnia is a risk factor for depression (Breslau et al., 1996; 
Ford & Kamerow, 1989; Hohagen et al., 1993) and years of research did not clarify the exact 
relationship between insomnia and depression (Riemann, 2007; Riemann et al., 2001). In an 
EEG, normal sleep can be partitioned into several stages. The first is progression from light 
sleep (N1 stage), followed by an “intermediate” level of sleep (stage N2) that leads to the 
“deep” sleep, which is characterized by slow delta waves on the EEG (stage N3). Stages N1-
N3 are part of non-rapid eye movement sleep, which alternates with rapid eye movement 
(REM) sleep throughout the night (Benca & Peterson, 2008). Depression is characterized by 
abnormal sleep (difficulty falling asleep, nocturnal awakenings, early-morning awakenings), 
decreased slow-wave sleep, shortened rapid eye movement (REM) latency, and increased 
REM density (Thase et al., 1997; Tsuno et al., 2005). Interestingly, total sleep deprivation 
improves symptoms in 40-60% of depressed patients (Giedke & Schwarzler, 2002; Wirz-
Justice & Van den Hoofdakker, 1999), which is thought to be due to activation of the limbic 
dopaminergic pathways (Ebert et al., 1994; Ebert et al., 1996). Additionally, the slow-wave 
sleep is marginally affected by antidepressant therapy (Sharpley & Cowen, 1995; Tsuno et 
al., 2005), indicating partial involvement of monoamines in sleep regulation.   
In addition to disruption in sleep pattern, depressed patients also exhibit alteration in 
biological rhythms, including appetite and hormone levels. Patients with seasonal affective 
disorders (SAD) have depressive symptoms during the winter months when daylight is 
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shorter. The bright light therapy has been effectively used to treat SAD (Lam, 2006) and non-
seasonal depression (Terman & Terman, 2005) and is thought to work by shifting the 
circadian clock (Wirz-Justice et al., 2005). Similar to 5-HT, melatonin is derived from 
tryptophan and is a critical regulator of circadian rhythm. Depressed patients display 
altered melatonin release and abnormal melatonin levels (Rubin et al., 1992; Wetterberg, 
1999), particularly in the acute phase of depressive illness (Srinivasan et al., 2006). 
Antidepressant therapy increases melatonin (Srinivasan et al., 2006; Thompson et al., 1985). 
Of note, a pilot study that looked at the use of melatonin in addition to cortisol as a 
prognostic marker for depression found promising results (Buckley & Schatzberg, 2010).   
Genetic regulators of the molecular clock (Clock, Bmal1, Npas2, GSK3β, and Timeless) have 
been linked with various mood disorders (McClung, 2007). Mutant mouse models 
exhibiting point mutations on the Clock gene display anxiety-like and depressive-like 
behavior (Roybal et al., 2007) and increased dopamine transmission in the ventral tegmental 
area (VTA) (McClung et al., 2005; Nestler & Carlezon, 2006), suggesting  that the Clock gene 
regulates dopamine signaling. Interestingly, there is circadian rhythm with regards to 
concentration, release, and synthesis of 5-HT, norepinephrine, and dopamine (Barassin et 
al., 2002; Shieh et al., 1997; Weiner et al., 1992), as well as in the expression and activity of 
monoamine receptors (Kafka et al., 1983; Wesemann & Weiner, 1990; Witte & Lemmer, 
1991), indicating a link between monoamine signaling and circadian rhythm.  
9. Future directions: Moving towards a systems biology approach 
Based on these findings, it is unlikely that a single biomarker can describe a multifactorial 
disorder like depression. Data from the last decades indicate that alterations in MDD are 
interconnected (Figure 1). This figure illustrates that there are neuroanatomical, 
neurobiochemical, neuroimmune, neuroendocrine, genetic, and metabolic mechanisms 
underlying MDD. Given the involvement of various biological systems, it is no surprise that 
depression is characterized by heterogeneous molecular and clinical manifestations, which 
complicate the search for depressive biomarkers.  Therefore, uncovering the etiology and 
mechanism underlying depression necessitates modification of clinical and pre-clinical 
study designs and the use of combinatorial approaches to assess multiple phenotypic 
variances.    
To obtain an in-depth clinical and biological assessment of depression, methodological 
aspects that should be considered when conducting clinical studies include obtaining a 
detailed family, medical, drug, and experiential history, performing longer patient follow-
up (6 months to 1 year), assessing for metabolic, psychosomatic, and behavioral symptoms, 
and collecting blood samples for biological assessment of disease or changes in symptoms. 
This information can aid in identifying genetic, environmental, and biological factors that 
contribute to patient-specific depressive behavior, which can further delineate behavioral 
and biological alterations that differ or overlap between depressed patients.  
Animal studies offer several advantages including lower cost, subject availability, and ease 
in brain and blood sample accessibility. In addition, the behavioral effects of drugs, genetics, 
and environment are more feasible to investigate in animal models of depression since the 
genome and the environment can be easily manipulated. Despite apparent advantages in 
using animals for depression studies, pre-clinical models of depression suffer from lack of 
face and construct validity (Nestler & Hyman, 2010). Depressive symptoms are challenging 
to model in animals given that diagnosis and prognosis are based on empirical clinical 
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observations and patients’ phenomenological accounts. In an effort to better assess clinical 
depressive measures in pre-clinical studies, the National Institute of Mental Health has 
adopted a set of constructs, known as the Research Domain Criteria (RDoC) 
(http://www.nimh.nih.gov), that are useful in conducting animal studies. The RDoC 
provides a framework in which scientific approaches like genomics and neuroscience can be 
used to interrogate for specific domains including negative affect and cognition. It remains 
to be seen if the use of RDoC will result in definitive findings that are likely to be replicated 
and validated.  
 
 
 
Fig. 1. Biological Alterations in Depression. Impairment in the HPA axis, neural circuitry, 
neuroendocrine, neuroimmune, neuronal signaling, neurogenesis, and metabolic functions 
have been observed in depressed patients, resulting in symptom heterogeneity. As shown, 
bidirectional communication among several pathways exists (i.e. crosstalk between 
sympathetic nervous system and inflammatory markers). Cellular (genetic) and molecular 
(proteomic) alterations in depression can be identified by performing global gene and 
protein expression analyses between healthy controls and depressed individuals (bottom 
left), leading to identification of depression molecular signatures. 
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Advancements in methodologies and information technology have facilitated identification 
of molecular and neurochemical correlates of MDD. Optogenetics helps elucidate the inter-
relationship between neural circuitry, brain signaling, and biological response. Genomics, 
proteomics, epigenomics, and metabolomics provide an unbiased way to characterize 
biological alterations that underlie depressive behavior. In light of the many biological 
systems that are affected in depression, combinatorial approaches should be used to 
examine changes in various (cellular, molecular, biochemical, and behavioral) phenotypes, 
providing us with a comprehensive disease model.   
Research studies conducted over the last forty years have not led to a detailed 
understanding of the mechanisms underlying MDD. Although this may seem disappointing 
at first, advances in technology and scientific approach indicate that the road to elucidating 
depression is one filled with hope and excitement. 
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